We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+3.46%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$71.7M
(+24%)
Cap. Flow
+$61.6M
Cap. Flow
% of AUM
16.74%
Top 10 Holdings %
Top 10 Hldgs %
80.73%
Holding
256
New
50
Increased
99
Reduced
30
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$24.9M |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$23M |
| 3 |
Rithm Capital
RITM
|
+$2.6M |
| 4 |
Travere Therapeutics
TVTX
|
+$1.21M |
| 5 |
Ouster
OUST
|
+$907K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAVN
Raven Industries Inc
RAVN
|
+$1.53M |
| 2 |
LAZR
Luminar Technologies
LAZR
|
+$1.22M |
| 3 |
uniQure
QURE
|
+$1.09M |
| 4 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$1.09M |
| 5 |
AgEagle Aerial Systems
UAVS
|
+$783K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.83% |
| 2 | Healthcare | 12.69% |
| 3 | Technology | 1.7% |
| 4 | Industrials | 0.97% |
| 5 | Financials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cogent Biosciences
COGT
$6.68B
| $993K | 0.27% |
122,500
+32,500
| +36% | +$275K |
|
27
ClearPoint Neuro
CLPT
$454M
| $955K | 0.26% |
50,000
| – | – |
|
28
Merck
MRK
$315B
| $933K | 0.25% |
12,000
-3,196
| -21% | -$238K |
|
|
29
Travere Therapeutics
TVTX
$5.27B
| $897K | 0.24% |
+61,500
| New | +$1.21M |
|
|
MOR
30
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $876K | 0.24% |
45,500
+26,500
| +139% | +$567K |
|
31
Iovance Biotherapeutics
IOVA
$2.23B
| $872K | 0.24% |
33,500
+30,500
| +1,017% | +$793K |
|
|
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
| $864K | 0.23% |
50,000
+23,000
| +85% | +$423K |
|
33
Karyopharm Therapeutics
KPTI
$216M
| $841K | 0.23% |
5,433
+1,966
| +57% | +$285K |
|
34
Celldex Therapeutics
CLDX
$2.77B
| $836K | 0.23% |
25,000
| – | – |
|
35
Gilead Sciences
GILD
$167B
| $813K | 0.22% |
11,800
| – | – |
|
36
Axsome Therapeutics
AXSM
$11.8B
| $810K | 0.22% |
12,000
+2,000
| +20% | +$120K |
|
37
Microbot Medical
MBOT
$118M
| $794K | 0.22% |
100,000
| – | – |
|
38
Gyre Therapeutics
GYRE
$675M
| $790K | 0.21% |
24,333
+16,333
| +204% | +$561K |
|
|
ICAD
39
DELISTED
iCAD Inc
ICAD
| $779K | 0.21% |
+45,000
| New | +$789K |
|
40
BioXcel Therapeutics
BTAI
$27.4M
| $727K | 0.2% |
1,563
| – | – |
|
41
Coherus Oncology
CHRS
$216M
| $712K | 0.19% |
51,500
+40,500
| +368% | +$574K |
|
42
Insmed
INSM
$23.5B
| $683K | 0.19% |
24,000
+22,900
| +2,082% | +$680K |
|
|
TCRR
43
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $673K | 0.18% |
41,000
+35,500
| +645% | +$717K |
|
|
MFA
44
MFA Financial
MFA
$960M
| $671K | 0.18% |
+36,540
| New | +$646K |
|
45
BioMarin Pharmaceuticals
BMRN
$11.5B
| $668K | 0.18% |
8,000
| – | – |
|
|
ONIT
46
Onity Group
ONIT
$344M
| $665K | 0.18% |
+21,477
| New | +$653K |
|
47
Aclaris Therapeutics
ACRS
$793M
| $650K | 0.18% |
+37,000
| New | +$840K |
|
48
Spyre Therapeutics
SYRE
$8.7B
| $644K | 0.17% |
3,700
+2,860
| +340% | +$520K |
|
49
ADC Therapeutics
ADCT
$172M
| $633K | 0.17% |
26,000
+9,000
| +53% | +$209K |
|
|
COOP
50
DELISTED
Mr. Cooper
COOP
| $633K | 0.17% |
+19,139
| New | +$639K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, AlphaCentric Advisors held 256 positions worth $368M, up 24% from $297M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
AlphaCentric Advisors deployed $61.6M of net new capital in Q2 2021, opening 50 new positions and adding to 99 existing holdings. Its largest new stake was Rithm Capital: 245,158 shares worth $2.6M.
By sector, the portfolio is most concentrated in Real Estate at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Azenta, an estimated $485K trimmed.
- AlphaCentric Advisors's largest Q2 2021 buy was Rithm Capital: 245,158 shares worth $2.6M.
- AlphaCentric Advisors added most to iShares MBS ETF in Q2 2021, an estimated $24.9M increase.
- AlphaCentric Advisors's biggest Q2 2021 reduction was Azenta, cutting an estimated $485K.
- AlphaCentric Advisors fully exited Raven Industries Inc in Q2 2021, selling an estimated $1.53M.
- AlphaCentric Advisors's ten largest holdings make up 81% of its $368M portfolio in Q2 2021.
- AlphaCentric Advisors opened 50 new positions and closed 47 in Q2 2021.
- AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $368M.
Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.